Assessment of Adeno-Associated Virus Serotype Tropism in Human Retinal Explants
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Advances in the discovery of the causes of monogenic retinal disorders, combined with technologies for the delivery of DNA to the retina, offer enormous opportunities for the treatment of previously untreatable blinding diseases. However, for gene augmentation to be most effective, vectors that have the correct cell-type specificity are needed. While animal models are very useful, they often exhibit differences in retinal cell surface receptors compared to the human retina. This study evaluated the use of an ex vivo organotypic explant system to test the transduction efficiency and tropism of seven different adeno-associated virus type 2 (AAV2) serotypes in the human retina and retinal pigment epithelium-choroid-AAV2/1, AAV2/2, AAV2/4, AAV2/5, AAV2/6, AAV2/8, and AAV2/9-all driving expression of GFP under control of the cytomegalovirus promoter. After 7 days in culture, it was found that AAV2/4 and AAV2/5 were particularly efficient at transducing photoreceptor cells and that AAV2/5 was highly specific to the outer nuclear layer, whereas AAV2/8 displayed consistently low transduction of photoreceptors. To validate the authenticity of the organotypic culture system, the transduction of the same set of AAVs was also compared in a pig model, in which sub-retinal injections in vivo were compared to cultured and transduced organotypic cultures ex vivo. This study shows how different AAV serotypes behave in the human retina and provides insight for further investigation of each of these serotypes for gene augmentation-based treatment of inherited retinal degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“expression of RPE65 protein in humans, and to result in improvement in visual acuity, pupillary light reflex, visual fields, and ambulatory vision that was closely correlated with the area of the retina that received treatment.(6) Further, no adverse immune responses or extra-ocular spread of AAV2-RPE65 was detected.”
BackgroundSelf-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 2×
“More than 15 years ago, researchers took advantage of this accessibility and the nonpathogenicity of adeno-associated virus (AAV) to deliver AAVs to the sub-retinal space and demonstrated that AAV-mediated gene replacement therapy could restore vision in a canine model of RPE65-associated LCA.2 The efficacy demonstrat…”
BackgroundMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationComparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review
Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L. E., Jayaram, P., & Khan, K. S. (2007) · BMJ · doi:10.1136/bmj.39048.407928.be · Cited by 827
Positional cloning of the gene associated with X-linked juvenile retinoschisis
Sauer, C. G., Gehrig, A., Warneke-Wittstock, R., Marquardt, A., Ewing, C. C., Gibson, A., Lorenz, B., Jurklies, B., & Weber, B. H. F. (1997) · Nature Genetics · doi:10.1038/ng1097-164 · Cited by 497 · cited 2×
“Another example of an inherited disease that would benefit more from treatment with an AAV serotype that transduces the inner retina is the juvenile onset macular disease X-linked retinoschisis, which is caused by mutations in the gene RS1.(30) Patients with retinoschisis develop cystic spaces in the retina, predomina…”
BackgroundHigh-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Natkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138
Novel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Mowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Cited by
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Gonzalez-Cordero, A., Goh, D., Kruczek, K., Naeem, A., Fernando, M., kleine Holthaus, S.-M., Takaaki, M., Blackford, S. J. I., Kloc, M., Agundez, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.027 · Cited by 77
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Self-citationEngineered Capsids for Efficient Gene Delivery to the Retina and Cornea
Frederick, A., Sullivan, J., Liu, L., Adamowicz, M., Lukason, M., Raymer, J., Luo, Z., Jin, X., Rao, K. N., & O'Riordan, C. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.070 · Cited by 35
“40 The merits of using an organotypic explant approach to test the viral transduction efficiency and tropism of different AAV serotypes in human retina and RPE choroid has been demonstrated, 40 and while there was evidence of variability in outer nuclear layer (ONL) transduction ef-ficiency across…”
Han, I. C., Burnight, E. R., Ulferts, M. J., Worthington, K. S., Russell, S. R., Sohn, E. H., Mullins, R. F., Stone, E. M., Tucker, B. A., & Wiley, L. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.159 · Cited by 30
“, Mount Prospect, IL), and sectioned using a vibrating tissue slicer (Leica VT1000 S Vibratome; Leica Microsystems, Wetzlar, Germany) as described previously.(24) Sections were blocked in immunocytochemical blocking buffer for thicker sections and labeled as described previously.”
BackgroundMethodSelf-citationWiley, L. A., Boyce, T. M., Meyering, E. E., Ochoa, D., Sheehan, K. M., Stone, E. M., Mullins, R. F., Tucker, B. A., & Han, I. C. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.222 · Cited by 30
“13,14 In rat models, we noted no clinically apparent inflammation based upon fundus examination and optical coherence tomography (OCT) of AAV-injected eyes, 14 in contrast to the severe inflammation seen following subretinal delivery of helper-dependent adenovirus 5 (HDAd5).”
Self-citationvan der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021267 · Cited by 14
“Thirdly, there was AAV2/4, a recombinant subtype of AAV2 that particularly transduces photoreceptors [91].”
Background
Metadata
- Authors
- Wiley, L. A., Burnight, E. R., Kaalberg, E. E., Jiao, C., Riker, M. J., Halder, J. A., Luse, M. A., Han, I. C., Russell, S. R., Sohn, E. H., Stone, E. M., Tucker, B. A., & Mullins, R. F.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2018-04
- Volume
- 29
- Issue
- 4
- Pages
- 424-436
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2769664417
- Cited by
- 68
- References
- 16
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.